Brief: Galapagos presented new data at ICML 2025 from Cohort 3 of ATALANTA-1 in relapsed/refractory indolent NHL patients
18/06/2025 22:44
June 18 (Reuters) - Galapagos NV GLPG.AS: GALAPAGOS PRESENTED NEW DATA AT ICML 2025 FROM COHORT 3 OF ATALANTA-1 IN RELAPSED/REFRACTORY INDOLENT NHL PATIENTS, DEMONSTRATING HIGH COMPLETE RESPONSE AND MRD NEGATIVITY RATES WITH CAR-T CANDIDATE GLPG5101 Source text: ID:nGNX8fqXv5 Further company coverage: GLPG.AS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Lakefront Announces Sale Of Preclinical Car-T Programs To Armed Cell Therapeutics
RBC upgrades Lakefront Biotherapeutics to 'outperform' on gamgertamig prospect
Brief: U.S. FDA Grants Orphan Drug Designation To Gamgertamig For The Treatment Of Pemphigus
Brief: Lakefront Biotherapeutics H1 Net Profit From Continuing Operations €15.8 Mln
Brief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline